Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $64.00 at Wedbush

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price upped by Wedbush from $47.00 to $64.00 in a research note released on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on XENE. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Robert W. Baird raised their price target on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday. Guggenheim reiterated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday. Finally, HC Wainwright boosted their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $71.94.

Xenon Pharmaceuticals Stock Down 3.4%

NASDAQ XENE opened at $60.61 on Tuesday. The firm has a market cap of $5.04 billion, a P/E ratio of -13.90 and a beta of 0.91. The business’s 50-day moving average price is $42.95 and its 200 day moving average price is $41.56. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the firm earned ($0.84) EPS. As a group, analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer owned 6,000 shares in the company, valued at approximately $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Neo Ivy Capital Management bought a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $2,001,000. JPMorgan Chase & Co. increased its stake in Xenon Pharmaceuticals by 11.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after purchasing an additional 142,452 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Xenon Pharmaceuticals by 34.6% during the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock valued at $31,934,000 after acquiring an additional 262,109 shares during the period. American Century Companies Inc. purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter worth about $21,280,000. Finally, Westfield Capital Management Co. LP lifted its position in shares of Xenon Pharmaceuticals by 4.6% in the third quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company’s stock worth $48,424,000 after purchasing an additional 53,461 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 topline results show azetukalner produced a statistically significant reduction in focal‑onset seizure frequency, positioning the drug for an NDA submission targeted in Q3 2026 — a major clinical milestone that drove the earlier sharp rally. GlobeNewswire: X-TOLE2 Results Reuters: Trial Meets Main Goal
• Positive Sentiment: Multiple brokerages raised price targets and maintained bullish ratings (HC Wainwright, Deutsche Bank, Needham, Wells Fargo, Wedbush), reflecting upwardly revised sales and valuation assumptions after the Phase 3 readout. Benzinga: Analyst Upgrades
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement, indicating the exchange processed material news that subsequently drove heavy intraday activity. (News pending/halt was lifted following the topline release.)
• Neutral Sentiment: Yesterday’s massive intraday rally — driven by the trial news — created rapid re‑rating and higher volatility; that squeeze can produce follow‑through profit‑taking and larger volume swings. 247WallSt: Big One‑Day Gain
• Negative Sentiment: Xenon announced a proposed underwritten public offering of $500M of common shares (with a 30‑day option for an additional $75M). Issuing new equity after a large run‑up creates dilution risk and puts selling pressure on the stock even though proceeds could fund commercialization and ongoing trials. GlobeNewswire: Offering MSN: Offering Coverage

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.